A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder
Step 1: Enter the Amount in the Vial Type the total peptide amount listed on your vial in milligrams, such as 25 mg or 50 mg
Methods We queried the PubMed, Cochrane, and Embase databases to identify prospective RCTs using inclusion criteria: 1) patients diagnosed with IC, 2) interventions included relevant treatments, 3) comparisons were a specified control or placebo, 4) outcomes were mean differences for individual symptoms and structured questionnaires
These evaluations will determine whether specific peptide compounds should ultimately be added to the 503A bulks list, which would formally permit their use in compounding under defined conditions
CLA may support gradual body composition improvements when combined with diet and exercise
Important: This article is for informational purposes only and not intended nor written to substitute medical advice